JP2002065808A - Package for stably preserving plastic vessel holding medical solution containing amino acid - Google Patents

Package for stably preserving plastic vessel holding medical solution containing amino acid

Info

Publication number
JP2002065808A
JP2002065808A JP2000260182A JP2000260182A JP2002065808A JP 2002065808 A JP2002065808 A JP 2002065808A JP 2000260182 A JP2000260182 A JP 2000260182A JP 2000260182 A JP2000260182 A JP 2000260182A JP 2002065808 A JP2002065808 A JP 2002065808A
Authority
JP
Japan
Prior art keywords
package
amino acid
vessel
container
gas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000260182A
Other languages
Japanese (ja)
Inventor
Norio Toda
則夫 遠田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NISSHIN SEIYAKU KK
Original Assignee
NISSHIN SEIYAKU KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NISSHIN SEIYAKU KK filed Critical NISSHIN SEIYAKU KK
Priority to JP2000260182A priority Critical patent/JP2002065808A/en
Publication of JP2002065808A publication Critical patent/JP2002065808A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To seal a medical solution containing amino acids which undergoes oxidation decomposition into a blowing-filled and sealed medical plastic bottle and to pack the bottle in a gas-impermeable packing material to obtain a package with a free-oxygen scavenger stored in a space between the vessel and the packing material. SOLUTION: When a glass ampoule or vial is used as a vessel for the medical solution, the fear of glass fragments getting into the medical solution or injuring fingers when the vessel is opened is eliminated and disposal of a used vessel is facilitated. Since a heat sterilization process is not required as is necessary for other plastic bag packages for transfusion, the addition of a stabilizer to the medical solution and resulting troubles can be avoided. Conventionally, a solution containing amino acids is unstable in its quality and cannot be supplied to the market unless contained in glass ampoules, but the stability of the vessel can be maintained over a long period by sealing and packing the container by use of a gas-impermeable barrier film with the free-oxygen scavenger sealed in the package.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、医療用プラスチッ
ク容器を用いる場合のL−システイン、アミノ酢酸、グ
リチルリチンアンモニウム塩を含有する薬液の溶解・調
製方法を簡易化し、かつ当該薬液の長期間の保存を可能
にした包装体に関する。
The present invention relates to a method for dissolving and preparing a drug solution containing L-cysteine, aminoacetic acid and glycyrrhizin ammonium salt when a medical plastic container is used, and to store the drug solution for a long time. The present invention relates to a package that enables the following.

【0002】[0002]

【従来の技術】従来から、L−システイン、アミノ酢
酸、グリチルリチンアンモニウム塩を含むアミノ酸含有
薬液は、抗アレルギー性肝疾患治療剤として、慢性肝疾
患における肝機能異常の改善や、湿疹、皮膚炎、蕁麻
疹、皮膚掻痒症などの治療に広く用いられている。そし
て、このものは一般にガラス製のアンプルやバイアル瓶
に充填されて市販されている。
2. Description of the Related Art Conventionally, a drug solution containing an amino acid containing L-cysteine, aminoacetic acid, and glycyrrhizin ammonium salt has been used as a therapeutic agent for antiallergic liver disease, for improving hepatic dysfunction in chronic liver disease, eczema, dermatitis, It is widely used for the treatment of urticaria, pruritus, etc. This is generally marketed in glass ampules or vials.

【0003】アンプルやバイアル瓶はガラス製容器であ
るために重い上に破損しやすく、ガラス製アンプルの開
封時などは、ガラス微細片の薬液への混入や手指を傷め
ることがあり、薬液にアルカリを含む場合、ガラスフレ
ークの発生が懸念される。さらには使用済み容器の廃棄
処理においても手間がかかるという欠点があった。かか
る問題点の解決法として、ガラス製容器に比して軽量で
破損の恐れがない医療用のプラスチック容器が提案さ
れ、製品が取扱いやすくなり、使用後の焼却処分も容易
となるものである。
Since ampules and vials are glass containers, they are heavy and easily broken, and when opening glass ampules, fine glass fragments may be mixed into the chemical solution or damage the fingers. In the case of containing, there is a concern about generation of glass flakes. Further, there is a disadvantage that it takes time and effort to dispose of used containers. As a solution to such a problem, a medical plastic container that is lighter and less likely to be damaged than a glass container has been proposed, which makes the product easier to handle and incineration after use.

【0004】ところで、一般的にアミノ酸溶液は熱、
光、酸素等の影響により経時的に不安定であることが知
られており、アミノ酸輸液の場合、酸化防止のため種々
の工夫や努力がなされた。薬液への抗酸化剤の添加は気
管支痙攣やアナフィラキシーショックと言った副作用に
至ったり、加熱滅菌の工程で異臭を発生させたり、沈殿
を生じたりと問題も持ち込んだ。この様な問題を避ける
ためアミノ酸成分そのものを細かく規定し、脱酸素剤の
包装体内への配置の場合でも薬液成分としてのシステイ
ンをさけたり(特開平7−89856)、システインを
含む場合は、硫化水素吸着剤を脱酸素剤とともに包装体
内に配置するものがある(特開平7−61925)。特
にL―システインは酸素の存在下で分解が促進され、酸
化反応により著しく含量低下を来す。しかしながら、当
該溶液を医療目的で使用する場合は、薬液中の溶存酸素
を除去し、前記したようなガス非透過性のガラス製容器
内に充填し、かつガラス製容器内の空間部分を窒素など
の不活性ガスで置換することにより、酸素との接触をで
きる限り回避することで長期的に安定性を保持すること
ができるものである。
In general, amino acid solutions are heated,
It is known that it is unstable over time due to the influence of light, oxygen and the like. In the case of amino acid infusion, various efforts and efforts have been made to prevent oxidation. The addition of an antioxidant to the drug solution also caused problems such as side effects such as bronchospasm and anaphylactic shock, generation of an unusual odor during heat sterilization, and precipitation. In order to avoid such a problem, the amino acid component itself is finely defined, and cysteine as a chemical solution component is avoided even when the oxygen absorber is disposed in the package (Japanese Patent Application Laid-Open No. 7-89856). There is one in which a hydrogen adsorbent is placed in a package together with a deoxidizer (Japanese Patent Application Laid-Open No. 7-61925). In particular, the decomposition of L-cysteine is promoted in the presence of oxygen, and the content is significantly reduced by an oxidation reaction. However, when the solution is used for medical purposes, dissolved oxygen in the chemical solution is removed, and the solution is filled in a gas-impermeable glass container as described above, and the space in the glass container is filled with nitrogen or the like. By replacing with an inert gas, contact with oxygen can be avoided as much as possible to maintain stability for a long period of time.

【0005】これに対し、近年採用された医療用プラス
チック製容器は、高いガス透過性を有するため、この容
器内に充填すると、容器内の空間部分を不活性ガスで置
換しても、容易に容器壁を透過して外部に放出される。
また、同じ様に外部の酸素が容器内に進入することよ
り、当該溶液は酸素下にさらされることになる。その結
果、当該溶液は分解反応が進行し、当該溶液の変質が起
こることになる。従って、当該溶液の医療用プラスチッ
ク製容器の形態は、有用性の高いものであるが、安定性
を保持することが困難であり、アミノ酸を含有すること
により、種々の対策を必要とする。
[0005] On the other hand, medical plastic containers adopted recently have high gas permeability, so that when they are filled in this container, even if the space inside the container is replaced with an inert gas, it is easily used. It is emitted to the outside through the container wall.
Similarly, the solution is exposed to oxygen as external oxygen enters the container. As a result, the solution undergoes a decomposition reaction, and the solution deteriorates. Therefore, although the form of the medical plastic container of the solution is highly useful, it is difficult to maintain stability, and various measures are required by containing an amino acid.

【0006】以上のように、これまではL−システイ
ン、アミノ酢酸及びグリチルリチン酸アンモニウム塩を
含む当該溶液をガラス製容器でしか長期間安定に保存す
ることができなく、医療用プラスチック製容器の形態で
は不可能であり、他の医薬品が一般的に3年程度の有効
期間を有するのに対し、極めて短期間しか保存できな
く、実用化できないのが現状だったのである。
As described above, the solution containing L-cysteine, aminoacetic acid and ammonium glycyrrhizinate can only be stably stored in a glass container for a long period of time so far. However, while other drugs generally have a shelf life of about three years, they can only be stored for a very short period of time and cannot be put to practical use.

【0007】[0007]

【発明が解決しようとする課題】しかしながら、当該溶
液の医療用プラスチック製容器の形態での安定性を保持
することが困難であっても、当該溶液の溶解・調製の段
階で溶液中の溶存酸素を除去する操作を行ったものを、
医療用プラスチック製容器に充填し、容器内の空間部分
を不活性ガスで置換した後、密封し、その後の加熱滅菌
工程を要することなく直ちにガス非透過性の包装体に収
容後、包装体内を真空包装又は包装体内の酸素を除去す
ることにより、長期間安定に保存を可能とするものであ
る。
However, even if it is difficult to maintain the stability of the solution in the form of a medical plastic container, the dissolved oxygen in the solution may be dissolve at the stage of dissolving and preparing the solution. After performing the operation to remove
After filling the container into a medical plastic container, replacing the space in the container with an inert gas, sealing the container, immediately storing it in a gas-impermeable package without the need for a subsequent heat sterilization step, and then packing the package. By removing the oxygen in the vacuum packaging or the packaged body, it is possible to stably store for a long period of time.

【0008】[0008]

【課題を解決するための手段】本発明によれば、上記課
題を解決すべく鋭意研究した結果、L−システインなど
のアミノ酸含有薬液であっても無菌充填可能なブローフ
ィルシールの様なシステムを選べば、後処理的な加熱殺
菌工程を要せず、酸化防止のための添加剤の選択や、含
有アミノ酸の種類、亜硫酸塩の存在等の制限に煩わされ
ることなく、また、適切なガス非透過性の包装体を選定
し、当該包装体の内部空間に対し必要十分な無酸素状態
を形成する脱酸素剤を配置することで、溶解・調整時の
溶存酸素の除去、容器内の空間部分を不活性ガスで置換
を行うこと並びに真空包装するための特別な装置を要す
ることなく、長期間安定した包装体が得られることを見
いだし、この知見に基づき本発明を完成するに至ったも
のである。
According to the present invention, as a result of intensive studies to solve the above-mentioned problems, a system such as a blow-fill seal capable of aseptically filling even a chemical solution containing an amino acid such as L-cysteine has been developed. If selected, it does not require a post-treatment heat sterilization step, does not bother with the selection of additives for antioxidation, the type of amino acids contained, the presence of sulfites, etc. By selecting a permeable package and arranging a deoxidizer that forms a necessary and sufficient anoxic state in the internal space of the package, removal of dissolved oxygen during dissolution and adjustment, space in the container Was replaced with an inert gas, and it was found that a long-term stable package could be obtained without requiring a special device for vacuum packaging, and based on this finding, the present invention was completed. is there.

【0009】本発明によれば、ガス非透過性の包装体内
に封入された脱酸素剤の作用で、医療用プラスチック製
容器とガス非透過性包装体の間に存在する空気中の酸素
が、次いで当該容器内に存在する空間部分の酸素が吸収
される。これにより、医療用プラスチック製容器の保管
状態は、実質上無酸素状態とせしめることができ、当該
薬液の変質を防止でき、長期間の保存が可能となったも
のである。なお、流通や保存在庫中の取り扱いで包装体
内に微少ピンホールなどにより酸素存在が発生した場合
の検知として、通常の酸素検知剤(エージレス・アイ
他、色の変化で識別するもの)を脱酸素剤とともに包装
体内に配置しても良い。
According to the present invention, the oxygen in the air existing between the medical plastic container and the gas impermeable package is reduced by the action of the oxygen scavenger enclosed in the gas impermeable package. Next, oxygen in the space existing in the container is absorbed. As a result, the storage state of the medical plastic container can be made substantially oxygen-free, the chemical solution can be prevented from being deteriorated, and long-term storage is possible. Deoxygenation of ordinary oxygen detectors (ageless eye, etc., identified by color change) to detect the presence of oxygen due to minute pinholes in the package during distribution or handling in stock. It may be placed in the package together with the agent.

【0010】本発明に使用されるアミノ酸含有薬液と
は、特にL−システインである。この化合物を含有する
薬液の化合物濃度は、用途・用法により適宜求められ、
また、他の電解質や薬剤を配合してもよい。当該薬液を
密封するための医療用プラスチック製容器の材質は、医
薬品収納用という性格から安全性が高いものであって、
かつ、液体を通さないガス透過性の容器であれば特に制
限はないが、好ましくは、一般にポリエチレン、ポリプ
ロピレン、ポリ塩化ビニルなどの熱可塑性合成樹脂であ
る。
[0010] The amino acid-containing drug solution used in the present invention is L-cysteine. The compound concentration of the drug solution containing this compound is appropriately determined according to the use and usage,
Further, other electrolytes and drugs may be blended. The material of the medical plastic container for sealing the drug solution is highly safe from the property of storing pharmaceuticals,
The container is not particularly limited as long as it is a gas-permeable container that does not allow liquid to pass through, but is preferably a thermoplastic synthetic resin such as polyethylene, polypropylene, or polyvinyl chloride.

【0011】かかる医療用プラスチック製容器を包み込
むためのガス非透過性の包装体は、ガスバリアー特性を
示し、かつ液体非透過性であれば、いずれのものでもよ
い。例えば、内層/低密度ポリエチレン、中間層/エチ
レン・ビニルアルコール共重合体および外層/ナイロン
からなる積層体が包合されたものや、また内層/低密度
ポリエチレン、中間層/ナイロンおよび外層/酸化珪素
蒸着ポリエステルからなる積層体が包合されたもので、
内容物の確認ができる程度の透明性を有することが望ま
しいが、積層体フィルムはアルミ箔やアルミ蒸着フィル
ムをコートされたものでも良い。
The gas-impermeable package for enclosing the medical plastic container may be any material as long as it exhibits gas barrier properties and is liquid-impermeable. For example, those in which a laminate composed of an inner layer / low-density polyethylene, an intermediate layer / ethylene-vinyl alcohol copolymer and an outer layer / nylon are encapsulated, or an inner layer / low-density polyethylene, an intermediate layer / nylon and an outer layer / silicon oxide A laminate made of vapor-deposited polyester is included,
It is desirable to have transparency enough to confirm the contents, but the laminate film may be coated with aluminum foil or an aluminum vapor-deposited film.

【0012】次に、本発明に用いられる脱酸素剤は、包
装体の内部空間の酸素を速やかに吸収し除去するもの
で、かつ酸素吸収量が多いものが好ましい。当該脱酸素
剤には、例えば当該主成分として、アスコルビン酸又は
エリソルビン酸およびそれらの塩などの還元性の多価ア
ルコール類、鉄粉又は亜硫酸塩第一鉄塩などの無機塩類
を含み、任意の触媒を含むものが包合される。
Next, the oxygen scavenger used in the present invention is one which rapidly absorbs and removes oxygen in the internal space of the package and has a large oxygen absorption amount. The deoxidizer includes, for example, as the main component, reducing polyhydric alcohols such as ascorbic acid or erythorbic acid and salts thereof, iron powder or inorganic salts such as ferrous sulfite, and Those containing the catalyst are included.

【0013】市販のものとして、エージレスZ(登録商
標)(三菱瓦斯化学(株)製)などが挙げられ、エージ
レスZを用いた場合、当該脱酸素剤の吸収量は、例えば
当該空間内の空気量100mLあたりの酸素量としては
20mL以上である。
Examples of commercially available products include Ageless Z (registered trademark) (manufactured by Mitsubishi Gas Chemical Co., Ltd.). When Ageless Z is used, the absorption amount of the oxygen absorber is determined, for example, by the air in the space. The amount of oxygen per 100 mL is 20 mL or more.

【0014】つぎに、実施例、比較例および試験例を挙
げて本発明をさらに詳しく説明するが、これらに限定さ
れるものではない。
Next, the present invention will be described in more detail with reference to Examples, Comparative Examples and Test Examples, but is not limited thereto.

【0015】[0015]

【実施例1】グリチルリチンアンモニウム塩204g、
アミノ酢酸2000gおよびL−システイン77gを溶
解して100Lとし、メンブランフィルターでろ過し
た。ろ液を内容量20mLのポリエチレン製注射剤容器
に充填(無菌充填システムであるブローフィルシール
機:u.s.Automatic Liquid Pa
ckaging社製)し、容器内の空間部分を窒素で置
換し、密封した後、このプラスチック容器を内層/低密
度ポリエチレン、中間層/エチレン・ビニルアルコール
共重合体、外層/ナイロンの積層体からなるガス非透過
性包装体内に脱酸素剤「エージレスZ(登録商標)」三
菱瓦斯化学(株)製とともに収納し、密封した。
Example 1 204 g of glycyrrhizin ammonium salt,
2000 g of aminoacetic acid and 77 g of L-cysteine were dissolved to make 100 L, and filtered with a membrane filter. The filtrate is filled into a polyethylene injection container having a content of 20 mL (a blow-fill-seal machine as a sterile filling system: us Automatic Liquid Pa.
After replacing the space in the container with nitrogen and sealing the container, the plastic container is composed of a laminate of an inner layer / low density polyethylene, an intermediate layer / ethylene / vinyl alcohol copolymer, and an outer layer / nylon. It was housed in a gas impermeable package together with the oxygen scavenger “Ageless Z (registered trademark)” manufactured by Mitsubishi Gas Chemical Co., Ltd., and sealed.

【0016】[0016]

【実施例2】ガス非透過性包装体である内層/低密度ポ
リエチレン、中間層/エチレン・ビニルアルコール共重
合体、外層/ナイロンを除き、実施例1と同様にして、
内層/低密度ポリエチレン、中間層/ナイロン、外層/
酸化珪素蒸着ポリエステルの積層体からなる包装体を製
造した。
Example 2 The procedure of Example 1 was repeated except for the inner layer / low-density polyethylene, the middle layer / ethylene-vinyl alcohol copolymer, and the outer layer / nylon, which were gas impermeable packages.
Inner layer / low density polyethylene, middle layer / nylon, outer layer /
A package comprising a laminate of silicon oxide-deposited polyester was produced.

【0017】[0017]

【比較例1】ガス非透過性包装体である内層/低密度ポ
リエチレン、中間層/エチレン・ビニルアルコール共重
合体、外層/ナイロン及び内層/低密度ポリエチレン、
中間層/ナイロン、外層/酸化珪素蒸着ポリエステルの
積層体で包装する点を除き、実施例1と同様にして製造
した。
[Comparative Example 1] Inner layer / low-density polyethylene, middle layer / ethylene / vinyl alcohol copolymer, outer layer / nylon and inner layer / low-density polyethylene, which are gas-impermeable packagings
It was manufactured in the same manner as in Example 1 except that it was packaged with a laminate of an intermediate layer / nylon and an outer layer / silicon oxide-deposited polyester.

【0018】[0018]

【比較例2】グリチルリチンアンモニウム塩204g、
アミノ酢酸2000gおよびL−システイン77gを溶
解して100Lとし、メンブランフィルターでろ過し
た。ろ液を内容量20mLのガラスアンプル(通常アン
プル充填操作)に分注し、容器内の空間部分を窒素で置
換し、密封した後、加熱滅菌を行った。
Comparative Example 2 204 g of ammonium glycyrrhizinate,
2000 g of aminoacetic acid and 77 g of L-cysteine were dissolved to make 100 L, and filtered with a membrane filter. The filtrate was dispensed into a 20-mL glass ampoule (usually an ampoule filling operation), the space in the container was replaced with nitrogen, sealed, and then heat-sterilized.

【0019】[0019]

【定量試験】以上のようにして得られた包装体を種種の
条件下で保存した後、含有量の変動を調べる目的で、L
−システインの定量試験を行った。製造直後の値を10
0.0%として、経日数における含有量の結果を表1に
示す。
[Quantitative test] After the package obtained as described above was stored under various conditions, the amount of L
-A quantitative test of cysteine was performed. Immediately after production 10
Table 1 shows the results of the content in the number of days as 0.0%.

【0020】[0020]

【表1】 [Table 1]

【0021】表1の結果によれば、包装体内の薬物含有
量に関し、本発明の包装体であるガス非透過性の積層体
と脱酸素剤使用の実施例1、2が従来法である比較例1
及び比較例2のガラスアンプル使用の結果と比較して、
大幅に改善され、本発明である安定な保存用包装体とし
て有効であることが証明された。
According to the results shown in Table 1, with respect to the drug content in the package, the comparative examples 1 and 2 using the gas-impermeable laminate and the oxygen scavenger, which are the package of the present invention, are the conventional methods. Example 1
And compared with the result of using the glass ampule of Comparative Example 2,
It was greatly improved and proved to be effective as the stable storage package of the present invention.

【0022】[0022]

【発明の効果】以上の説明から明らかなように、本発明
によれば、L−システインなどのアミノ酸を含有する薬
液を通常のガラスアンプルと同様にして医療用プラスチ
ック製容器の形態で長期にわたり安定に保存することは
不可能であったが、ガス非透過性の積層体と共に脱酸素
剤を収納し、密封することにより、長期間にわたる保存
に成功することができたのである。
As is clear from the above description, according to the present invention, a drug solution containing an amino acid such as L-cysteine can be stably formed in a medical plastic container for a long period of time in the same manner as a normal glass ampule. Although it was impossible to store the oxygen-absorbing agent together with the gas-impermeable laminate, the oxygen-absorbing agent was successfully stored for a long period of time.

【0023】また、本発明によれば、医療用プラスチッ
ク製容器を用いるので、ガラスアンプルのカット時に発
生する薬液へのガラス微細片の混入がなく、かつ、軽量
で破損の恐れも少なく、しかもガラス製アンプルの開封
時における手指を傷めることがないなど取扱いに便利で
あるという利点もある。
Further, according to the present invention, since a medical plastic container is used, fine glass fragments are not mixed into a chemical solution generated when a glass ampule is cut, and the glass is lightweight and has little risk of breakage. There is also an advantage that it is convenient for handling, such as not damaging the fingers when opening the ampoule made.

【図面の簡単な説明】[Brief description of the drawings]

【図1】参考的な本発明の脱酸素剤を適用したガス非透
過性包装体の正面図
FIG. 1 is a front view of a reference gas impermeable package to which the oxygen scavenger of the present invention is applied.

【符号の説明】[Explanation of symbols]

1 アミノ酸含有薬液の医療用プラスチック製容器 2 脱酸素剤 3 ガス非透過性包装体 4 密封部 1 Medical Plastic Container for Amino Acid-Containing Chemical Solution 2 Oxygen Absorber 3 Gas-impermeable Packaging 4 Sealed Part

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 酸化分解を受けるアミノ酸含有薬液を医
療用プラスチック容器に入れ密封し、この容器をガス非
透過性包装材料で包装し、当該包装体内における上記医
療用プラスチック容器周囲の空間に対し、無酸素雰囲気
形成手段を施すことを特徴とするアミノ酸含有薬液包装
1. An amino acid-containing chemical solution which undergoes oxidative degradation is sealed in a medical plastic container, and the container is packed with a gas-impermeable packaging material. Amino acid-containing chemical liquid package characterized by applying an oxygen-free atmosphere forming means
【請求項2】 医療用プラスチック容器が無菌充填シス
テムであるブローフィルシールで生産された容器である
請求項1記載の包装体
2. The package according to claim 1, wherein the medical plastic container is a container produced by a blow fill seal which is an aseptic filling system.
【請求項3】 ガス非透過性包装材料の酸素透過度が0
〜3cc/m2・day・atm(25℃、50%R.
H.)である請求項1記載の包装体
3. The gas-impermeable packaging material has an oxygen permeability of 0.
~ 3 cc / m 2 · day · atm (25 ° C, 50%
H. 2. The package according to claim 1, wherein
【請求項4】 無酸素雰囲気形成手段が脱酸素剤であっ
て、これを包装体内に配置する請求項1記載の包装体
4. The package according to claim 1, wherein the oxygen-free atmosphere forming means is a deoxidizer, and is disposed in the package.
【請求項5】 アミノ酸含有薬液のアミノ酸成分がL−
システィン、アミノ酢酸である請求項1記載の包装体
5. The amino acid component of the amino acid-containing drug solution is L-amino acid.
The package according to claim 1, which is cysteine or aminoacetic acid.
JP2000260182A 2000-08-30 2000-08-30 Package for stably preserving plastic vessel holding medical solution containing amino acid Pending JP2002065808A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000260182A JP2002065808A (en) 2000-08-30 2000-08-30 Package for stably preserving plastic vessel holding medical solution containing amino acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000260182A JP2002065808A (en) 2000-08-30 2000-08-30 Package for stably preserving plastic vessel holding medical solution containing amino acid

Publications (1)

Publication Number Publication Date
JP2002065808A true JP2002065808A (en) 2002-03-05

Family

ID=18748227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000260182A Pending JP2002065808A (en) 2000-08-30 2000-08-30 Package for stably preserving plastic vessel holding medical solution containing amino acid

Country Status (1)

Country Link
JP (1) JP2002065808A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335380A (en) * 2002-05-17 2003-11-25 Otsuka Pharmaceut Factory Inc Package with function of oxygen indicator
WO2005004902A1 (en) * 2003-07-10 2005-01-20 Nipro Corporation Recombinant human serum albumin preparation accommodated in plastic container
WO2005014009A1 (en) * 2003-08-12 2005-02-17 Nippon Zoki Pharmaceutical Co., Ltd. Glycyrrhizin high-concentration preparation
WO2008037699A1 (en) * 2006-09-27 2008-04-03 Aseptic Technologies S.A. Process for providing an oxygen-free atmosphere within a container
WO2008146731A1 (en) * 2007-05-25 2008-12-04 Ajinomoto Co., Inc. Method for preparation of infusion solution for peripheral intravenous administration
JP2009153729A (en) * 2007-12-27 2009-07-16 Dainippon Printing Co Ltd Package bag for medical plastic container
US9908682B2 (en) 2007-01-09 2018-03-06 Allergan Pharmaceuticals International Limited Storage of ampoules containing pharmaceutical formulations using a sealed container comprising an oxygen scavenger

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335380A (en) * 2002-05-17 2003-11-25 Otsuka Pharmaceut Factory Inc Package with function of oxygen indicator
WO2005004902A1 (en) * 2003-07-10 2005-01-20 Nipro Corporation Recombinant human serum albumin preparation accommodated in plastic container
JPWO2005004902A1 (en) * 2003-07-10 2006-08-24 ニプロ株式会社 Recombinant human serum albumin preparation in plastic container
WO2005014009A1 (en) * 2003-08-12 2005-02-17 Nippon Zoki Pharmaceutical Co., Ltd. Glycyrrhizin high-concentration preparation
AU2004263036B2 (en) * 2003-08-12 2010-06-03 Nippon Zoki Pharmaceutical Co., Ltd. Glycyrrhizin high-concentration preparation
WO2008037699A1 (en) * 2006-09-27 2008-04-03 Aseptic Technologies S.A. Process for providing an oxygen-free atmosphere within a container
US9908682B2 (en) 2007-01-09 2018-03-06 Allergan Pharmaceuticals International Limited Storage of ampoules containing pharmaceutical formulations using a sealed container comprising an oxygen scavenger
WO2008146731A1 (en) * 2007-05-25 2008-12-04 Ajinomoto Co., Inc. Method for preparation of infusion solution for peripheral intravenous administration
JP2009153729A (en) * 2007-12-27 2009-07-16 Dainippon Printing Co Ltd Package bag for medical plastic container

Similar Documents

Publication Publication Date Title
KR100304846B1 (en) Package for container of liquid medicine containing bicarbonate and ph indicator
JP2890142B2 (en) Bicarbonate-containing powder formulation container and method for stabilizing the formulation
JP2022180486A (en) Intravenous infusion dosage form
JP4125957B2 (en) Method for improving the stability of pharmaceutical compositions
JP2021176896A (en) Parenteral dosage form of diltiazem
JP2002065808A (en) Package for stably preserving plastic vessel holding medical solution containing amino acid
JPS63186652A (en) Liquid agent for drug received in bag
JP2010515509A (en) Storage of ampoules containing pharmaceutical formulations using sealed containers containing oxygen scavengers
JP2016022092A (en) Edaravone-containing plastic container
JP2505329B2 (en) Package for storing chemical solutions containing bicarbonate compounds
JP2000175989A (en) Medicinal liquid container
JP4225416B2 (en) Methods for improving the stability of protein formulations
JP5079365B2 (en) Packaging method and manufacturing method of packaged goods
JP2527532B2 (en) New application of carbon dioxide generating oxygen absorber
JP2005006737A (en) Package for stably preserving amino acid-containing medical fluid housing plastic container
JP6823045B2 (en) Vinca alkaloid drug dosage form
JP2022516973A (en) Stable aqueous injectable solution of epinephrine
JP2004057321A (en) Adsorbed oxygen removed plastic container
JP2750373B2 (en) Method for stabilizing aqueous pharmaceutical solution and container
CN220431019U (en) Semi-permeable container packaging system
JPH10287375A (en) Package body for container containing medicament whose properties easily change by oxygen
JP2006306465A (en) External bag, alkaline chemical liquid filled container storing member using external bag and storage method for alkaline chemical liquid filled container
JPH119655A (en) Injection agent
JP7316559B2 (en) Liquid-filled combination container, container set, and liquid-filled container manufacturing method
KR20240004368A (en) Dexmedetomidine solution in a low-density polyethylene container.